Please login to the form below

Not currently logged in


This page shows the latest Zejula news and features for those working in and with pharma, biotech and healthcare.

Advair generics and acquisitions to hit GSK in 2019

Advair generics and acquisitions to hit GSK in 2019

These are its BCMA targeting candidate in fourth-line multiple myeloma, and Tesaro’s Zejula for first line maintenance ovarian cancer and PD-1 dostarlimab for endometrial cancer.

Latest news

More from news
Approximately 3 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...